Longitudinal DAT changes measured with [ 18 F]FE-PE2I PET in patients with Parkinson's disease; a validation study.

Longitudinal [F]FE-PE2I PET measurements in non-advanced PD demonstrate a striatal DAT decline consistent with previous SPECT and PET studies. No obvious changes of DAT availability were observed in the substantia nigra, indicating perhaps slower progression or compensatory changes. The effect sizes were numerically larger than reported in the literature for other DAT radioligands, suggesting that [F]FE-PE2I might detect smaller DAT changes, and can be well used as progression marker in clinical trials.